Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial
Zhigong Wei(Sichuan University), Xingchen Peng(Sichuan University)
Cited by 1
Related Papers
Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk
|Frontiers in Immunology|2023|40
Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study
|Journal of Translational Medicine|2022|32
Prognostic nomogram for adenoid cystic carcinoma in different anatomic sites
|Head & Neck|2020|29